Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel
NASDAQ:SVRA

Savara Q1 2026 Earnings Report

Savara logo
$5.27 0.00 (0.00%)
Closing price 05/14/2026 04:00 PM Eastern
Extended Trading
$5.16 -0.11 (-1.99%)
As of 04:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Savara EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.14
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Savara Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.50 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Savara Announcement Details

Quarter
Q1 2026
Date
5/13/2026
Time
Before Market Opens
Conference Call Date
Tuesday, May 12, 2026
Conference Call Time
7:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Savara's Q1 2026 Press ReleasePress Release
(8-K)
Savara's Q1 2026 Quarterly reportQuarterly report
(10-Q)

Savara Earnings Headlines

Savara Reports First Quarter Financial Results and Provides Business Update
May 12 at 4:05 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20260512677993/en/savara-reports-first-quarter-financial-results-and-provides-business-update/
Assessing Savara (SVRA) Valuation After FDA Extends Priority Review For Molgramostim
April 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/assessing-savara-svra-valuation-fda-170321523.html
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel
 |  Brownstone Research (Ad)
Analysts Offer Insights on Healthcare Companies: Savara (SVRA) and Rhythm Pharmaceuticals (RYTM)
April 17, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RYTM-Q/pressreleases/1365090/analysts-offer-insights-on-healthcare-companies-savara-svra-and-rhythm-pharmaceuticals-rytm/
Savara Announces New Employment Inducement Grant
April 17, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260417883325/en/savara-announces-new-employment-inducement-grant/
Savara gets FDA review extension for lead asset
April 16, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4575623-savara-gets-fda-review-extension-for-lead-asset
See More Savara Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Savara? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Savara and other key companies, straight to your email.

About Savara

Savara (NASDAQ:SVRA) (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant. In addition, Savara has in-licensed Brensocatib, a dipeptidyl peptidase 1 (DPP-1) inhibitor originally developed by AstraZeneca, which is being evaluated in clinical trials for non-cystic fibrosis bronchiectasis (NCFBE) and nontuberculous mycobacterial (NTM) lung infections. These programs reflect the company’s strategy of leveraging existing pharmacological data to streamline development in orphan respiratory indications.

Founded in 2013 and headquartered in Austin, Texas, Savara conducts its research and development activities primarily in North America and Europe. The company collaborates with academic institutions, patient advocacy groups and strategic partners to support clinical trial execution, regulatory interactions and eventual commercialization planning. Savara’s management team brings together expertise in drug development, regulatory affairs and respiratory medicine, all aimed at transforming care for patients with life-threatening pulmonary disorders.

View Savara Profile
Earnings Tools